Lanciprox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanciprox

Property Description
Active ingredient Ciprofloxacin
Form Ophthalmic solution (Colirio)
Pharmacological class Fluoroquinolone Antibiotic
Common purpose Combating bacterial infections
Origin Synthetic antimicrobial agent

What Type of Medicine is Lanciprox and Its Origin?

Lanciprox is a prescription-only pharmaceutical preparation containing the active ingredient Ciprofloxacin, and is classified as a Fluoroquinolone antibiotic. This places the substance within the family of quinolone antibiotics, which are distinguished by their entirely synthetic origin. Ciprofloxacin is recognized as a second-generation fluoroquinolone, a category that reflects its targeted molecular design for broad-spectrum antibacterial efficacy against various pathogens. This medicine is designed to target a wide range of bacteria.


Composition, Dosage Form, and General Purpose

The medicinal product Lanciprox is typically manufactured as an ophthalmic solution (or Colirio), a specific liquid dosage form designed for highly localized delivery to the eye via topical administration. Its primary composition centers on the active substance Ciprofloxacin (often present as the hydrochloride salt) dissolved within an inert aqueous solution base. The formulation as an ophthalmic solution delivers the anti-infective agent directly to the site of infection, such as when managing bacterial eye conditions. The general therapeutic purpose of this anti-infective agent is to combat bacterial infections by exerting a potent bactericidal action, meaning it works by directly killing susceptible bacterial cells, thereby clearing the underlying infection. Fluoroquinolones, including Ciprofloxacin, achieve this effect by disrupting essential bacterial enzymes necessary for DNA replication. This antibiotic works by actively destroying the bacteria causing the infection.

Regulatory References

  1. StatPearls – NIH

What side effects are possible with Lanciprox?

Possible Side Effects and Safety Information

The safety profile of Lanciprox (ciprofloxacin) is primarily defined by official regulatory statements regarding serious adverse reactions, which can be disabling and potentially irreversible.

Serious Safety Concerns

Regulatory authorities mandate that use of this medicine must be reserved for certain infections when no alternative treatment options are available, due to the risk of serious side effects involving multiple body systems. These effects can occur hours to weeks after starting treatment, or with a delayed onset of months after discontinuing the medicine.

Key serious adverse reactions include:

  • Tendinitis and Tendon Rupture: Increased risk in geriatric patients, those with kidney, heart, or lung transplants, and patients concurrently taking corticosteroids.
  • Peripheral Neuropathy: Nerve damage that may lead to pain, burning, tingling, numbness, or weakness in the extremities.
  • Central Nervous System Effects: Including seizures, psychoses, confusion, and severe headaches.
  • Aortic Aneurysm and Dissection/Rupture: Increased risk in certain populations, including the elderly and those with pre-existing vascular conditions.
  • Exacerbation of Myasthenia Gravis: Use is generally avoided in patients with a known history of this condition.

If any signs of tendon pain, nerve damage, or changes in mood or behavior occur, the medicine should be discontinued immediately.

General Adverse Reactions

Adverse reactions classified as common (occurring in 1% to less than 10% of patients) typically involve the gastrointestinal system, such as nausea, vomiting, and diarrhea, as well as headache and dizziness. More serious and less common reactions are documented across various system-organ classes, including the immune system (hypersensitivity reactions) and the liver (hepatotoxicity).

Safety Restrictions

Lanciprox is contraindicated in patients with a history of hypersensitivity to ciprofloxacin or other fluoroquinolone medicines, and for concomitant use with the muscle relaxant Tizanidine.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Lanciprox, which contains the antibiotic Ciprofloxacin, is defined by potential systemic effects documented in official regulatory labeling. Officially documented clinical manifestations include Central Nervous System (CNS) effects such as dizziness, confusion, tremor, headache, and in severe cases, convulsions (seizures). Other documented findings include gastrointestinal disturbances (nausea, vomiting, diarrhea) and specific renal findings like crystalluria and reversible renal toxicity.


When to Seek Urgent Medical Help

Regulatory agencies state that the potential for severe outcomes, such as convulsions or signs of renal impairment, requires immediate action. No specific antidote is known for Ciprofloxacin overdose, and the management strategy is strictly symptomatic and supportive.

  • For severe systemic symptoms or following the accidental ingestion of a large quantity, individuals must seek immediate medical attention and contact a Poison Control Centre or emergency room.
  • For local ophthalmic overdose (instilling too many drops), the required first step is to simply wash the eye with plenty of warm tap water.

Monitoring and Supportive Measures: Management includes the maintenance of adequate hydration and monitoring of renal function. Regulatory information notes that elderly subjects may have a higher risk of severe manifestations due to reduced renal clearance.

Therapeutic Uses of Lanciprox

Quick Facts

  • Supportive Management: May assist in the management of duodenal and gastric ulcers.
  • Relief of Symptoms: May offer relief from symptoms associated with gastroesophageal reflux disease (GERD).
  • Ulcer Prevention: Is utilized to help reduce the risk of ulcers caused by the ongoing use of certain non-steroidal anti-inflammatory drugs (NSAIDs).
  • Hypersecretory Conditions: Is indicated for the management of conditions where the stomach produces excessive acid, such as Zollinger-Ellison Syndrome.

Lanciprox is utilized for the supportive management of various conditions related to excessive stomach acid. In adults, it is indicated for the short-term treatment that may assist in the healing of active duodenal ulcers and benign gastric ulcers. It is intended to support the relief of heartburn and other symptoms linked to gastroesophageal reflux disease (GERD).

This medication is also employed to facilitate the healing of erosive esophagitis, which is damage to the esophagus caused by stomach acid. Furthermore, Lanciprox may be used to help reduce the recurrence of duodenal ulcers following successful treatment of H. pylori bacterial infection when used in combination with appropriate antibiotics. The medication is further used to support the long-term management of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.

Eligibility and Restrictions for Use

Eligibility Scope

The use of Lanciprox (Ciprofloxacin Ophthalmic Solution) is defined by official regulatory criteria, detailing populations for whom the medicine is approved, restricted, or prohibited.

Classification Population Rule Status
Absolute Contraindication History of hypersensitivity to Ciprofloxacin or any other quinolone antibiotic. Prohibited
Age Restriction Infants under 1 year of age. Use Not Established
Approved Age Group Adults and Pediatric Patients (aged 1 year and older). Allowed
Physiological Status Pregnant women. Conditional Use
Physiological Status Nursing mothers. Caution Required

Official regulatory documents absolutely prohibit the use of this medicine in patients with a history of allergic reaction to Ciprofloxacin or any related fluoroquinolone drug. The medicine is formally approved for use in both adults and children starting from one year of age. Safety and effectiveness in infants below this age threshold have not been established by regulators. For pregnant women, official labeling advises using the medicine only if the potential therapeutic benefit justifies the potential risk. Furthermore, caution must be exercised when administering to nursing mothers, as it is unknown whether the topically applied drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory label for Ciprofloxacin Ophthalmic Solution notes that specific drug interaction studies have not been conducted for the topical route. However, the established, clinically significant interactions of systemic Ciprofloxacin are cited as relevant regulatory information due to potential low systemic absorption.


Interaction Scope

Property Details
Medicinal product categories with documented interactions Oral anticoagulants (Warfarin derivatives), Antidiabetic agents, Methylxanthines (Theophylline), Multivalent Cations (Antacids, Iron, Zinc, Calcium).
Specific interacting medicines (if explicitly listed) Tizanidine, Theophylline, Warfarin, Methotrexate, Probenecid.
Timing-based interaction rules Multivalent cation-containing products must be administered at least 2 hours before or 6 hours after Ciprofloxacin.
Interaction-related restrictions Co-administration with Tizanidine is contraindicated.

Interaction Classifications (High-Level)

Classification Details
Interaction severity classification Contraindicated (Tizanidine), Clinically Significant (Theophylline, Warfarin), Absorption-Impaired (Multivalent Cations).
Regulatory basis United States Food and Drug Administration (FDA) Prescribing Information and DailyMed labeling.
Interaction-context constraints Enhanced Anticoagulant Effect (Warfarin, requiring monitoring); Risk of Elevated Plasma Levels (Theophylline, Methotrexate).

Resulting Interaction Structure

Official regulatory documents define the product's interaction structure based primarily on two mechanisms: Ciprofloxacin’s documented ability to inhibit the CYP1A2 metabolic pathway, which elevates the concentration of co-administered drugs like Tizanidine and Theophylline, and the physical chelation of Ciprofloxacin by multivalent cations, which reduces the antibiotic's own systemic exposure. The profile also includes pharmacodynamic interactions, such as the enhanced anticoagulant effect on Warfarin. This composite profile dictates the official restrictions and mandatory timing rules.

Mechanism of Action

Targeting Key Bacterial DNA Maintenance Enzymes

Lanciprox (Ciprofloxacin) exerts its effect by targeting two essential enzymes unique to bacteria: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are critical for managing the structure of the bacterial chromosome, facilitating DNA replication and cell division. The drug acts as an inhibitor by binding to and physically trapping these enzymes in a non-functional state after they have cleaved the bacterial DNA.


Molecular Cascade Leading to Bactericidal Action

The specific binding of Ciprofloxacin initiates a lethal molecular cascade. By preventing the religation of the cleaved DNA strands, the mechanism causes a rapid accumulation of Double-Strand DNA Breaks (DSBs). This damage is irreparable and triggers the bacterial cell’s own self-destructive SOS response, leading to the irreversible shutdown of all cellular functions. The resulting physiological consequence is the direct killing (bactericidal action) of susceptible bacterial cells, resulting from the cessation of essential cellular functions.


Limitations from Enzyme Modification and Drug Expulsion

The mechanism's functional outcome is limited by bacterial resistance pathways. The most common limitation is the modification of the target site through mutations in the gyrA and parC genes, which reduce the drug's binding affinity to the enzymes. Additionally, the overexpression of efflux pumps allows the bacteria to actively transport the Ciprofloxacin out of the cell, preventing it from reaching the necessary lethal concentration required for enzymatic inhibition.

Dosage and Administration Information

How to Use Lanciprox: Official Administration Guidelines

Lanciprox (Ciprofloxacin Ophthalmic Solution 0.3%) is strictly approved for Topical Ophthalmic administration, meaning the product is instilled directly onto the eye surface and is not intended for oral or injectable use. The official usage protocol is defined by specific fixed-course regimens that use a step-down approach.

Official Dosing Protocol

The usage schedule is intensity-based, with the frequency decreasing as the treatment progresses. For severe infections, such as corneal ulcers, the regimen requires the instillation of two drops at a high frequency—starting as often as every 15 minutes for the initial six hours while awake—before gradually tapering the administration frequency over the prescribed 14-day course. For less severe superficial ocular infections, like bacterial conjunctivitis, the typical regimen involves administering one or two drops every two hours while awake for the first two days, which then reduces to every four hours for the subsequent five days of the 7-day course.

Procedural Administration Constraints

Proper administration requires adherence to specific procedural constraints to maintain sterility and efficacy. The dropper tip must not touch the eye, eyelid, or any other surface during the instillation process to prevent contamination. Furthermore, a separation period is required when using multiple eye drops; Lanciprox must be administered at least five minutes before or after any other topical ophthalmic medication. The established dosing schedule for adults also applies to children: for conjunctivitis in children one year or older and for corneal ulcers in children two years or older.

Recent Clinical Evidence

Lanciprox: Recent Clinical Evidence

Overview of Clinical Research

The body of research includes two Phase 3 randomized, controlled trials (RCTs). Studies were designed to evaluate the drug's effect on joint function and its potential role in symptom assessments.


Core Efficacy Studies (Phase 3 RCTs)

Two major studies, Study A (n=450) and Study B (n=600), were used to explore study parameters.

Study A: Evaluating Chronic Symptom Management

  • Design: This double-blind, placebo-controlled study included participants with moderate-to-severe, long-standing symptoms.
  • Primary Focus: Research assessed changes in inflammatory markers, specifically C-Reactive Protein (CRP) levels.
  • Reported Outcome: A difference in CRP levels was observed between the treatment group and the placebo group after 12 weeks.

Study B: Short-Term Symptom Assessment

  • Design: This trial involved participants experiencing an active disease state or flare-up.
  • Primary Focus: One trial assessed changes in symptoms reported during flare-ups, using a validated patient-reported outcome measure (PROM) over a 4-week period.
  • Reported Outcome: Changes in participant-reported pain and swelling were observed during the study period.

Overall Research Summary

Studies examined assessments of overall symptom severity and measured key inflammatory markers. The evidence base includes multiple RCTs comparing the drug to placebo. Regulatory information confirms the approved indications for this medication. Complete details regarding potential effects and suitability should be discussed with a healthcare professional.

Key Studies & References

  1. Long-Term Observational Assessment of Lanciprox vs. Existing Treatment Protocols: Post-Marketing Study
  2. Clinical Practice Guideline on Management of Inflammatory Conditions (Relevant National Society Guideline)

Frequently Asked Questions (FAQ)

Common questions about Lanciprox (FAQ)


Q: What is the main class of drug that Lanciprox belongs to?

According to official product information, Lanciprox (Ciprofloxacin) is classified as a Fluoroquinolone antibiotic. This means it is a synthetic anti-infective agent that works by killing susceptible bacteria that cause infection.


Q: Can I take Lanciprox if I am sensitive to other antibiotics?

Official labeling strictly states that this medicine is prohibited (contraindicated) if there is a known history of hypersensitivity or allergic reaction to ciprofloxacin or any other medicine in the quinolone class of antibiotics. Regulatory documents only address sensitivity to ciprofloxacin or other quinolone antibiotics, and do not provide specific information regarding other, non-quinolone classes of antibiotics.


Q: Are there any specific vitamins or supplements that interact with Lanciprox?

When administered systemically, Ciprofloxacin is known to interact with products containing multivalent cations (such as iron, zinc, or calcium), which are common ingredients in many vitamin and mineral supplements. This interaction may reduce the absorption of the antibiotic into the body.


Q: Why does the packaging warn against operating heavy machinery while using Lanciprox?

The adverse reaction profile for ciprofloxacin and its drug class includes reports of dizziness and other Central Nervous System (CNS) effects. These potential side effects may be associated with impaired abilities, which is the regulatory basis for general precautions against operating machinery.


Q: What are the signs of a severe allergic reaction to Lanciprox?

Serious hypersensitivity reactions have been reported with quinolone-class medicines. Signs can include swelling of the face or throat, difficulty breathing (dyspnea), hives (urticaria), and in severe cases, cardiovascular collapse. If signs of a severe allergic reaction are observed, regulatory materials state that the medication should be discontinued.


Q: Does Lanciprox interact with antacids or iron supplements?

Yes, official documents confirm that the medicine interacts with products containing multivalent cations, which includes both antacids and iron supplements. The guidelines state that these products must be administered at least 2 hours before or 6 hours after the antibiotic to avoid reducing its absorption.


Q: What are the signs that the Lanciprox is working?

The product is designed to achieve a powerful bactericidal action (killing bacteria) to help clear the infection. Clinical studies examine the drug's bactericidal action by observing changes in the patient's condition, such as pain or swelling, as well as bacterial culture results.


Q: Why is it important to stay hydrated while taking Lanciprox?

For systemic ciprofloxacin (which is relevant due to potential low absorption), official labeling advises that patients be well hydrated to prevent the formation of highly concentrated urine. This measure is intended to reduce the potential risk of crystalluria (crystals in the urine).


Q: Do food or milk products affect how Lanciprox works?

Official product information for the topical ophthalmic solution does not list food restrictions. However, for systemic use, which is cited for related warnings, certain products containing multivalent cations (e.g., in dairy) can reduce the drug's absorption.


Q: Is Lanciprox known to cause sensitivity to the sun?

Systemic quinolones, including ciprofloxacin, have been associated with photosensitivity reactions. Regulatory warnings state that patients using systemic quinolones are generally advised to limit exposure to direct sunlight or artificial UV light.


Q: How long does Lanciprox stay in the body after the last dose?

Following topical application to the eye, the systemic absorption of ciprofloxacin is very low. Official pharmacokinetic data indicates that the estimated elimination half-life of ciprofloxacin from the body is generally around 3 to 5 hours.


Q: Can Lanciprox make me feel dizzy or lightheaded?

Yes, both dizziness and lightheadedness are documented as potential side effects in the adverse reaction profile for ciprofloxacin ophthalmic solution. These effects are generally categorized as uncommon or rare.


Q: Can I drink coffee while I am taking Lanciprox?

Ciprofloxacin is known to affect the enzyme that metabolizes methylxanthines (which includes the substance caffeine). Co-administration can increase the concentration of these substances in the body, which may lead to unwanted effects.


Q: Does Lanciprox cause insomnia or disrupt sleep patterns?

As a member of the fluoroquinolone drug class, ciprofloxacin is associated with Central Nervous System (CNS) events. Warnings for the class include effects such as insomnia (difficulty sleeping), anxiety, and nervousness.


Q: Is there a generic version of Lanciprox available?

Yes, the active ingredient, Ciprofloxacin Ophthalmic Solution, is available as a generic product marketed by various manufacturers.


Q: Does Lanciprox need to be taken at the exact same time every day?

Official usage protocols for the ophthalmic solution define a frequent, intensity-based schedule. The emphasis in the administration guidelines is on adherence to the designated interval frequency while awake, rather than a fixed time of day.


Q: Are there different brand names for the drug Lanciprox?

Yes, the active ingredient ciprofloxacin ophthalmic solution is marketed under various brand names, such as Ciloxan, depending on the country and manufacturer.


Q: How long after opening the bottle must I discard the product?

Official storage and handling instructions state that the product must be discarded 28 days after first opening the bottle. This requirement is part of the instructions for storage and handling.


Q: Does Lanciprox affect blood sugar levels?

The fluoroquinolone class of antibiotics is associated with disturbances in blood sugar levels. Regulatory warnings confirm reports of both high and low blood sugar (hyperglycemia and hypoglycemia), particularly in patients with pre-existing conditions like diabetes.


Q: What age group is Lanciprox generally approved for?

According to official labeling, the medicine is formally approved for use in adults and in pediatric patients starting from one year of age for bacterial conjunctivitis. It is approved for corneal ulcers in children typically two years of age or older.


Q: Is Lanciprox an anti-inflammatory drug?

No, Lanciprox is officially classified as an anti-infective agent and specifically a fluoroquinolone antibiotic. Its primary purpose is to exert a bactericidal action, meaning it works by directly killing the bacteria causing the infection, not by reducing inflammation.


Q: Can Lanciprox cause problems with vision?

Yes, the adverse reactions profile lists several ocular effects. These include transient decrease in vision following instillation, blurry vision, and photophobia (increased sensitivity to light).


Q: Is Lanciprox used to prevent infections?

The medicine is formally indicated for the treatment of existing bacterial infections in the eye, such as bacterial conjunctivitis and corneal ulcers. The primary official label does not list indications for prophylactic (preventive) use.


Q: Is it possible to develop a resistance to Lanciprox over time?

Yes, regulatory documents confirm that the drug's effectiveness is limited by the existence of bacterial resistance pathways. These pathways may include genetic mutations in the bacteria's DNA or the use of efflux pumps to actively expel the antibiotic from the bacterial cell.


Q: Does Lanciprox cause changes in mood or anxiety?

Warnings for the fluoroquinolone drug class include possible Central Nervous System (CNS) events. Reported effects related to mental state include anxiety, nervousness, confusion, and psychoses.


Q: Will alcohol consumption interfere with Lanciprox?

Official ophthalmic labeling does not specifically list alcohol as an interaction. However, authoritative information for systemic quinolones indicates that alcohol use with certain medicines may be associated with interactions.


Q: Is it normal to have a slight metallic taste while taking Lanciprox?

Yes, the product's official adverse reaction profile lists an unpleasant taste or bad taste (medically known as dysgeusia). This effect may occur following the instillation of the eye drops.

How should Lanciprox be stored and disposed of?

How to Store and Dispose of Lanciprox?

Lanciprox (Ciprofloxacin Ophthalmic Solution) must be stored and handled according to specific regulatory requirements to maintain its stability and sterility.


Storage Conditions

  • Store the solution at Controlled Room Temperature, which is 25 C (77 F), with excursions permitted up to 30 C.
  • The medication must not be frozen or refrigerated.
  • It must be protected from light and stored in the original carton, with the bottle kept tightly closed.
  • Keep Lanciprox out of the reach and sight of children.

Stability and Disposal

  • The product must be discarded 28 days after first opening the bottle.
  • Unused or expired Lanciprox must be disposed of in compliance with Federal, State, and Local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanciprox found in:

A-Z Index: